HUE033072T2 - Staphylococcus aureus antigének immunogén készítményei - Google Patents

Staphylococcus aureus antigének immunogén készítményei Download PDF

Info

Publication number
HUE033072T2
HUE033072T2 HUE11804822A HUE11804822A HUE033072T2 HU E033072 T2 HUE033072 T2 HU E033072T2 HU E11804822 A HUE11804822 A HU E11804822A HU E11804822 A HUE11804822 A HU E11804822A HU E033072 T2 HUE033072 T2 HU E033072T2
Authority
HU
Hungary
Prior art keywords
protein
kda
clfa
artificial sequence
polypeptide
Prior art date
Application number
HUE11804822A
Other languages
English (en)
Hungarian (hu)
Inventor
Lakshmi Khandke
Akihisa Nonoyama
Tamara Shafer Hodge
Sandeep Nema
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of HUE033072T2 publication Critical patent/HUE033072T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
HUE11804822A 2010-12-22 2011-12-21 Staphylococcus aureus antigének immunogén készítményei HUE033072T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061426476P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
HUE033072T2 true HUE033072T2 (hu) 2017-11-28

Family

ID=45444677

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11804822A HUE033072T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének immunogén készítményei
HUE16193095A HUE047263T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének stabil immunogén készítményei

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16193095A HUE047263T2 (hu) 2010-12-22 2011-12-21 Staphylococcus aureus antigének stabil immunogén készítményei

Country Status (18)

Country Link
US (1) US20130259896A1 (enExample)
EP (2) EP3150222B1 (enExample)
JP (1) JP6097478B2 (enExample)
KR (2) KR101808398B1 (enExample)
CN (1) CN103826656B (enExample)
AU (1) AU2011346535B2 (enExample)
BR (1) BR112013016153A2 (enExample)
CA (1) CA2819120C (enExample)
DK (2) DK3150222T3 (enExample)
ES (2) ES2614815T3 (enExample)
HU (2) HUE033072T2 (enExample)
IL (1) IL226793B (enExample)
MX (1) MX350170B (enExample)
PL (2) PL3150222T3 (enExample)
PT (2) PT2654784T (enExample)
RU (1) RU2570730C2 (enExample)
SI (2) SI3150222T1 (enExample)
WO (1) WO2012085872A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1793849A2 (en) 2004-09-22 2007-06-13 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
SA114350400B1 (ar) 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN107096020A (zh) 2009-06-22 2017-08-29 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
EP2575870B1 (en) * 2010-06-04 2016-12-07 Wyeth LLC Vaccine formulations
AU2012266880A1 (en) * 2011-03-16 2013-10-03 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EA201690859A1 (ru) * 2013-12-04 2016-11-30 Гликоваксин Аг Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
WO2015155310A1 (en) * 2014-04-10 2015-10-15 Biotech Tools S.A. Hsp-free allergen preparation
WO2019036313A1 (en) * 2017-08-16 2019-02-21 Merck Sharp & Dohme Corp. CONJUGATED PNEUMOCOCCAL VACCINE FORMULATIONS
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
WO2020027466A1 (ko) 2018-07-28 2020-02-06 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
CA3164420A1 (en) * 2020-01-13 2021-07-22 Jonathan Clapper Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス セラム ラボラトリ−ズ コミツシヨン 抗原活性を有するアミノ酸配列
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1999027109A2 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS)
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
CA2777661C (en) * 1998-08-31 2014-10-21 Inhibitex, Inc. Multicomponent vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
ATE249839T1 (de) 2000-06-08 2003-10-15 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
MXPA03011133A (es) 2001-06-07 2004-12-06 Wyeth Corp Formas mutantes de holotoxina de colera como adyuvante.
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN100359327C (zh) 2001-06-15 2008-01-02 英希比泰克斯公司 识别凝血酶阴性的葡萄球菌和金黄色葡萄球菌的表面蛋白的交叉反应性单克隆抗体和多克隆抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US9296795B2 (en) 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1793849A2 (en) * 2004-09-22 2007-06-13 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
MX337528B (es) * 2006-03-30 2016-03-09 Glaxosmithkline Biolog Sa Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
CL2007003209A1 (es) * 2006-11-07 2008-05-09 Acambis Inc Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
CN107096020A (zh) * 2009-06-22 2017-08-29 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物

Also Published As

Publication number Publication date
IL226793B (en) 2019-02-28
EP3150222A1 (en) 2017-04-05
PT3150222T (pt) 2020-02-03
EP2654784A2 (en) 2013-10-30
ES2769425T3 (es) 2020-06-25
HK1197370A1 (en) 2015-01-16
HUE047263T2 (hu) 2020-04-28
PT2654784T (pt) 2017-02-13
US20130259896A1 (en) 2013-10-03
DK2654784T3 (en) 2017-02-13
MX2013006960A (es) 2013-07-15
DK3150222T3 (da) 2020-01-27
CN103826656B (zh) 2015-08-26
KR101808398B1 (ko) 2017-12-12
AU2011346535B2 (en) 2015-09-24
MX350170B (es) 2017-08-28
SI2654784T1 (sl) 2017-01-31
RU2013128277A (ru) 2015-01-27
BR112013016153A2 (pt) 2017-07-11
CA2819120C (en) 2016-07-05
EP3150222B1 (en) 2019-11-27
EP2654784B1 (en) 2016-12-07
CA2819120A1 (en) 2012-06-28
SI3150222T1 (sl) 2020-02-28
PL2654784T3 (pl) 2017-08-31
WO2012085872A3 (en) 2012-08-30
RU2570730C2 (ru) 2015-12-10
PL3150222T3 (pl) 2020-05-18
JP6097478B2 (ja) 2017-03-15
JP2012136518A (ja) 2012-07-19
KR20150129071A (ko) 2015-11-18
ES2614815T3 (es) 2017-06-02
AU2011346535A1 (en) 2013-06-13
WO2012085872A2 (en) 2012-06-28
KR20130114210A (ko) 2013-10-16
CN103826656A (zh) 2014-05-28

Similar Documents

Publication Publication Date Title
HUE033072T2 (hu) Staphylococcus aureus antigének immunogén készítményei
US9724402B2 (en) Neisseria meningitidis composition and methods thereof
CN1359301B (zh) 含有与Aβ1-10残基内的表位特异性结合的抗体的药物组合物及其应用
ES2728282T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
CN109862908A (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物
HUE026089T2 (hu) NGF elleni antitestek és eljárás alkalmazásukra
HUE027823T2 (hu) Immunstimuláló oligonukleotidok
HU229968B1 (hu) Sztreptokokkusz oltóanyag
CN109890415A (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物
US11472850B2 (en) Neisseria meningitidis composition and methods thereof
JP2000505091A (ja) 抗―Fcαレセプター抗体からなる治療用多重特異的化合物
CN102657855A (zh) 用于进行抗葡萄球菌接种的免疫原性组合物
DE69738271T2 (de) Rotavirus-impfstoff
JP2016516721A (ja) トキソイド、組成物および関連方法
Zahid et al. Otitis media: recent advances in otitis media vaccine development and model systems
CN109069424A (zh) 脂质体疫苗
AT503297B1 (de) Allergen-spezifische antikörper
Felix et al. The preparation of anti-typhoid serum in the horse for therapeutic use in man
DE60125959T2 (de) Unterscheidung zwischen gnrh-i und gnrh-ii
US20220233668A1 (en) Glycopeptide vaccine
Silva et al. Caries vaccine: current reality or remote future
BR102018005192A2 (pt) Globulina imune, método para preparar uma globulina imune, método para tratar infecção, método para fornecer imunoterapia e composição de plasma agrupado
Bcl et al. The ADP-Ribosylating CTA1-DD Adjuvant
SA113340369B1 (ar) تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US20160008462A1 (en) Veterinary composition and method of improving livability of animals, promoting live weight gain in mammals and birds, enhancing the effectiveness of immunization, and preventing and/or treating infectious diseases (variants)